CRISM Therapeutics Corporation (LSE:CRTX), a healthcare and pharmaceuticals company, has announced a retail share offer aimed at raising up to £100,000. The offer consists of new ordinary shares priced at 9 pence each and forms part of the company’s broader funding strategy for its Phase 2 clinical trial evaluating irinotecan-ChemoSeed in patients with glioblastoma. The offer is open to UK investors and is being coordinated by SP Angel Corporate Finance LLP. Completion remains subject to the admission of the new shares to trading on AIM.

More about CRISM Therapeutics Corporation

CRISM Therapeutics Corporation is a UK-based clinical-stage biotech company focused on improving cancer treatment through localized, sustained chemotherapy delivery. Its lead technology, ChemoSeed, is designed for implantation directly into tumors or surgical margins—particularly in the treatment of glioblastoma—allowing therapeutic agents to bypass the blood–brain barrier and more effectively target cancerous tissue.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.